IFN-beta

IFN-beta Overview

English Name	Interferon beta	Approved Drugs	1
Drugs in Clinical Trials	6	Target Synonym	Interferon Beta 1，Interferon， Beta 1， Fibroblast，IFNB，IFB，IFF，Interferon-beta，IFN-beta，Fibroblast interferon，IFNB1，Interferon beta
Highest Development Stage	Approved

English Name	Interferon beta
Target Synonym	Interferon Beta 1，Interferon， Beta 1， Fibroblast，IFNB，IFB，IFF，Interferon-beta，IFN-beta，Fibroblast interferon，IFNB1，Interferon beta
Approved Drugs	1
Drugs in Clinical Trials	6
Highest Development Stage	Approved

IFN-beta Product List

Product Category
Protein (3)
Product Status
Launched (3)
Species
Human (2)Mouse (1)
Tag
Fc Tag (1)His Tag & Avi Tag (2)
Conjugate
Unconjugated (1)Biotin-labeled (2)

Cat. No.	Species	Host	Product Description	Order Now
IFB-H5254	Human	HEK293	Human IFN-beta Protein, Fc Tag (MALS verified)	Add to Cart
IFB-H82E4	Human	HEK293	Biotinylated Human IFN-beta Protein, His,Avitag™ (MALS & SPR verified)	Add to Cart
IFB-M82E3	Mouse	HEK293	Biotinylated Mouse IFN-beta Protein, His,Avitag™ (MALS & SPR verified)	Add to Cart

Total: 3

IFN-beta Background

Human type I interferons (IFNs) are a large subgroup of interferon proteins that help regulate the activity of the immune system. Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The IFN-β proteins are produced in large quantities by fibroblasts. They have antiviral activity that is involved mainly in innate immune response. Two types of IFN-β have been described, IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate. Furthermore, IFN-β1 can bind to a IFNAR1-IFNAR2 heterodimeric receptor, and can also function with IFNAR1 alone and independently of Jak-STAT pathways.

IFN-beta Synonyms

IFNB1,Interferon beta,IFN-beta,IFB,IFNB

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Dazukibart	PF-06823859	Phase 3 Clinical	Pfizer Inc	Dermatomyositis; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Muscular Diseases; Myositis; Polymyositis	Details
Peginterferon beta-1a (CinnaGen)		Phase 3 Clinical	Cinnagen	Multiple Sclerosis, Relapsing-Remitting	Details
VSV-IFNbeta-NIS		Phase 2 Clinical	Vyriad	Angioimmunoblastic T-cell Lymphoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Histiocytoma; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Melanoma; Multiple Myeloma; Mycosis Fungoides; Myelodysplastic Syndromes; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck	Details
VSV-hIFNbeta-NIS (University of Tennessee)		Phase 1 Clinical	The University Of Tennessee	Endometrial Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell; Multiple Myeloma	Details
MEM-288	MEM-288	Phase 1 Clinical	Memgen	Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms	Details
SCD-153	SCD-153	Phase 1 Clinical	Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Johns Hopkins University, Sun Pharma Advanced Research Company Ltd	Alopecia Areata	Details